FDA clears Covidien's latest Nellcor continuous respiratory monitor

Mon, 07/30/2012 - 1:08pm
Mass Device

Covidien wins FDA clearance for its Nellcor Bedside SpO2 patient monitoring system with continuous monitoring.

Covidien logo

Medical device maker Covidien (NYSE:COV) touted FDA clearance for the latest in its line of Nellcor patient monitors, the Bedside SpO2.

The device continuously monitors SpO2 and pulse rate for adult, pediatric and neonatal patients, providing access to comprehensive respiratory trends and subtle variations.

"Healthcare professionals on the general care floor, and in other lower-acuity areas of the hospital, need critical patient information at their fingertips so they can respond quickly to health threats," Covidien respiratory & monitoring solutions president Robert White said in prepared remarks. "By giving them ready access to a patient's respiratory history, the system allows them to focus on delivering efficient, high-quality care, not gathering and managing data."


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.